Skip to search formSkip to main contentSkip to account menu

iodine I 131 monoclonal antibody CC49

Known as: 131I-MOAB CC49, I 131 Monoclonal Antibody CC49, I131 MOAB CC49 
A radioimmunoconjugate of the humanized monoclonal antibody CC49 labeled with iodine I 131. Iodine I 131 monoclonal antibody CC49 delivers beta and… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
  • 2007
  • Corpus ID: 12189706
The t r ihydroxamate bifunctional chelating agent (BCA), trisuccin, has been shown to be a potential ligand for radiolabeling of… 
2002
2002
Radioisotopes with moderate half-lives are essential for conventional radioimmunotherapy using tumor-selective MAbs which require… 
2001
2001
The prospects of radiolabeled antibodies in cancer detection and therapy remain promising. However, efforts to achieve cures… 
1999
1999
Progress in the use of monoclonal antibodies (MAbs) for the treatment of solid tumors is limited by a number of factors… 
1999
1999
One of the problems in achieving cures with radioimmunotherapy is that hematological toxicity limits the quantity of radiolabeled… 
1997
1997
A phase II study to evaluate the safety and efficacy of the 125I-radiolabeled anti-TAG-72 monoclonal antibody, CC49, as a… 
1997
1997
Preclinical studies have demonstrated that recombinant IFN-alpha (rIFN-alpha) can enhance the tumor associated glycoprotein 72… 
Highly Cited
1995
Highly Cited
1995
Monoclonal antibody (MAb) CC49 reacts with tumor-associated glycoprotein (TAG)-72, a human pancarcinoma antigen. In clinical… 
Highly Cited
1995
Highly Cited
1995
CC49 is a second-generation monoclonal antibody (MAb) that has high affinity for the tumor-associated pancarcinoma antigen tumor… 
1995
1995
The ability to identify and expand effector cells with reactivity against tumor-associated antigens (TAA) is critical for…